Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance

Subramanian Senthilkumaran; Sambathkumar Sasikumar; Florence Benita; Ponniah Thirumalaikolundusubramanian

首页> 外文期刊>Indian journal of Anaesthesia >Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance

【24h】

Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance

机译：葡萄糖共转运蛋白2钠抑制剂：患者安全性和临床重要性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Indian journal of Anaesthesia》 |2017年第6期|共2页
作者
Subramanian Senthilkumaran; Sambathkumar Sasikumar; Florence Benita; Ponniah Thirumalaikolundusubramanian;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类外科学;
关键词
入库时间 2022-08-18 08:54:06

相似文献

外文文献
中文文献
专利

1. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials [J] . Patoulias Dimitrios, Stavropoulos Konstantinos, Imprialos Konstantinos, Diabetes research and clinical practice . 2019,第期

机译：血糖样肽-1受体激动剂在钠葡萄糖共转运蛋白-2抑制剂的顶部血糖疗效和安全性与单独的葡萄糖共转运蛋白-2抑制剂相比：随机对照试验的系统回顾和荟萃分析
2. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial [J] . Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts . 2020,第6期

机译：患有2型糖尿病患者的新型葡萄糖共转运蛋白-2抑制剂的疗效和安全性，新的葡萄糖共转运蛋白-2抑制剂：24周，随机，双盲，主动对照试验
3. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：患有2型糖尿病患者的新型葡萄糖共转运蛋白-2抑制剂的疗效和安全性，新的葡萄糖共转运蛋白-2抑制剂：24周，随机，双盲，主动对照试验
4. Improving Patient Safety by Reusing Clinical Routine Data - An Expert Survey on Patient Safety Indicators [C] . Michael SCHALLER, Werner O. HACKL, Elske AMMENWERTH eHealth Conference . 2018

机译：通过重用临床常规数据提高患者安全性 - 患者安全指标的专家调查
5. Mechanisms Underlying Cardiovascular Benefits of Sodium Glucose Co-transporter-2 Inhibitors: Myocardial Substrate or Sodium/Hydrogen Exchanger? [D] . Baker, Hana Elisabeth. 2020

机译：葡萄糖共转运蛋白-2抑制剂的心血管益处潜在的机制：心肌基质或钠/氢气交换器？
6. Patient-Specific Risk Factors and Clinical Correlates of Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Co-Transporter-2 Inhibitors [O] . Manoj Reddy Somagutta, Maria Kezia Lourdes L Pormento, Namrata Hange, 2021

机译：患者特异性危险因素及嗜钠糖尿病患者患者的患者胰腺癌酮症病毒
7. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial [O] . Mala Dharmalingam, S. R. Aravind, Hemant Thacker, 2020

机译：Remogliflozin Etabonate，一种新的葡萄糖共转运蛋白-2抑制剂的疗效和安全性，2型糖尿病患者：24周，随机，双盲，主动对照试验

Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance

著录项

相似文献

相关主题

期刊订阅